Showing 1 – 20 of 8607
Relevance | Newest | Oldest |
  • JAMA February 24, 2015

    Figure 4: Crude Incidence Rates of Ischemic and Hemorrhagic Complications During 1-Year Follow-up in Patients With and Without OAC Resumption

    Incidence rates of (A) new ischemic and (B) hemorrhagic events comparing all surviving patients who restarted oral anticoagulation (OAC) vs those who did not restart OAC. Analyses were based on all patients with complete 1-year follow-up data.
  • JAMA February 24, 2015

    Figure 1: Flow Diagram of Participating Centers, Study Participants, and 3-Tiered Analyses

    Hematoma enlargement (analysis n = 853) was defined as a relative volume increase >33% on follow-up imaging. Overall, 160 patients received surgical hematoma evacuation; of these, we included 78 patients with follow-up imaging before surgery and excluded 82 patients without follow-up imaging before surgery. Analysis of functional long-term outcome included all the patients in the study (n = 1176). Long-term outcome was assessed at 1 year. Analysis of oral anticoagulation (OAC) resumption (n = 719) compared surviving patients who restarted OAC vs patients who did not restart OAC. CT indicates computer tomography; ICH, intracerebral hemorrhage; INR, international normalized ratio; IVH, intraventricular hemorrhage. (For details on center selection, see eFigure 1 in the Supplement.)
  • Potential Target for ALS Therapy

    Abstract Full Text
    JAMA. 2012; 308(13):1310-1310. doi: 10.1001/jama.2012.13154
  • JAMA February 22, 2012

    Figure 3: Survival and Hospital Discharge

    Percentages were calculated daily; the denominator at all times represents all patients in each group with the exception of 1 patient in the full-feeding group who was lost to follow-up and censored in these plots at day 36. The solid lines represent the proportion of patients surviving at each time; dashed lines represent the proportion of patients discharged from the hospital at each time. The areas above the solid lines represent the proportion of patients who have died in each group at each time; the areas below the dashed lines represent the proportion of patients alive and discharged from the hospital at each time. Areas between the solid and dashed lines represent the proportion of patients alive but still hospitalized in each group at each time.
  • JAMA October 12, 2011

    Figure 5: Proportion Curves of 60-Day Hospital Survival and Unassisted Breathing

    The omega-3 (n-3) supplement comprised the n-3 fatty acids docosahexaenoic acid and eicosapentaenoic acid, the omega-6 γ-linolenic acid, and antioxidants. Percentages were calculated daily; all patients completed follow-up and the denominators were the complete cohorts (143 for the omega-3 [n-3] group and 129 for the control group). Solid lines are survival curves and represent proportion of patients surviving at each period; dashed lines represent the proportion of patients breathing without assistance at each period. The areas above the solid lines represent the proportion of patients who have died in each group at each period; the areas below the dashed lines represent the proportion of patients alive and free of mechanical ventilation in each group at each period. Areas between the solid and dashed lines indicate percentages alive and still receiving mechanical ventilation in each group at each period.
  • JAMA October 27, 2010

    Figure 3: Functional Trajectories by Baseline Functioning

    The unadjusted mean number of functional limitations of surviving cohort members is shown. Error bars indicate 95% confidence intervals. Interpretive Example: Groups that had no functional or mild to moderate limitations before sepsis had a stable trajectory before sepsis but developed about 2 new limitations after sepsis. But patients with severe limitations at baseline had a modest increase from a baseline of 6.99 to 7.98 at their first survey after sepsis (Table 3).
  • JAMA July 28, 2010

    Figure 3: Meta-analytic Survival Curve

    Based on mortality rates among patients that experienced delirium during hospitalization from studies listed in the eFigure. Circles are proportional to study size and depict the proportion of surviving individuals. For specified periods, aggregated weighted estimates for survival are depicted by a horizontal line with corresponding 95% confidence intervals (gray area). For example, 2 to 4 years after delirium, 45% of individuals are still alive.
  • JAMA March 17, 2010

    Figure 2: Cumulative Proportions of Patients Discontinuing Chemotherapy by Specified Day by Age

    Across all the times on the x-axis, the n associated with the denominator is constant and includes all patients who initiate adjuvant chemotherapy (n = 513). P values using χ2 tests indicated significant differences in probability of chemotherapy discontinuation across age categories for surviving patients within 30 days (P = .01), 120 days (P = .007), and 150 days (P = .001) after initiating chemotherapy.
  • Getting It Right When Things Go Wrong

    Abstract Full Text
    JAMA. 2010; 303(10):977-978. doi: 10.1001/jama.2010.256
  • JAMA June 3, 2009

    Figure: Survival Curves for Infants Born Alive According to Gestational Age

    All surviving infants were followed up for 365 days; therefore, only the initial numbers of infants at risk are shown. Error bars are 95% Kaplan-Meier survival estimates at 60 minutes, 24 hours, 28 days, and 12 months.
  • JAMA October 15, 2008

    Figure 5: Survival Rate by Treatment

    The probability of surviving to any 1 of 5 clinically relevant end points (loss of 4 points on the ADAS-cog [Alzheimer Disease Assessment Scale], increase in global CDR [Clinical Dementia Rating] score, loss of 15 points on the ADCS-ADL [Alzheimer Disease Cooperative Study activities of daily living] scale, institutionalization, or death). P value was determined by Cox proportional hazards regression model.
  • Surviving Cardiac Arrest: Location, Location, Location

    Abstract Full Text
    JAMA. 2008; 300(12):1462-1463. doi: 10.1001/jama.300.12.1462
  • JAMA August 16, 2006

    Figure 5: Modeled Changes in CD4 Cell Count Over Time for Surviving Patients Who Received or Did Not Receive Antiretroviral Therapy, Lusaka, Zambia (April 2004-November 2005)

    CD4 cell count trajectories were estimated from mixed modeling using maximum likelihood estimation and a random effect for individual (see METHODS). Only those patients with repeat measures were included in the modeled estimates. ART indicates antiretroviral therapy.
  • JAMA August 11, 2004

    Figure 3: Serum Bactericidal Antibody Responses

    Percentage reduction in surviving bacterial colonies (percentage kill) for each M type, according to dose group, using serum obtained 14 days after the third vaccination in the indirect bactericidal assay compared with prevaccination levels. Circles represent individual volunteers; lines represent median values for each M type contained in the vaccine. Individuals with the same values appear as a single circle. Participants received 50 µg of vaccine on days 0, 28, and 56; 100 µg of vaccine on days 0, 28, and 112; or 200 µg of vaccine on days 0, 28, and 112.
  • JAMA October 22, 2003

    Figure: Proportion Surviving After Common Bile Duct Injury

    Proportion of patients surviving after cholecystectomy with or without common bile duct injury. *The mean age of those younger than 65 years was 54.8 years.
  • JAMA March 19, 2003

    Figure 2: Estimated Probability of Survival to Hospital Discharge Plotted Against Response Time

    Average fraction of surviving patients for each 2-minute interval. Lines indicate logistic regression models with time as independent variable fitted separately for each of the 2 groups.
  • Clinical Presentation of Inhalational Anthrax Following Bioterrorism Exposure: Report of 2 Surviving Patients

    Abstract Full Text
    free access
    JAMA. 2001; 286(20):2549-2553. doi: 10.1001/jama.286.20.2549
  • JAMA May 3, 2000

    Figure 2: Cumulative Survival Probabilities in Patients With Advanced-Stage (III and IV) BRCA-Associated and Sporadic Ovarian Cancers

    A, All BRCA-linked cases (n=81) vs sporadic cases (n=100). B, BRCA1-linked cases (n=61) vs sporadic cases (n=100). C, BRCA2-linked cases (n=20) vs sporadic cases (n=100). D, All stage III and IV BRCA-linked cases (n=81), stage III patients from Gynecologic Oncology Group (GOG) protocol 52 (n=349), institutional stage III and IV sporadic cases (n=100), and stage III and IV patients from GOG protocol 111 (n=386). Symbols represent time to most recent follow-up in surviving patients. Note variation in scale of x-axes.
  • Long-term Outcome of Children Surviving Massive Burns

    Abstract Full Text
    free access
    JAMA. 2000; 283(1):69-73. doi: 10.1001/jama.283.1.69